Leuprolide depot 3.75 I'm vs subcutaneous
Reading File
Finding Sources
Searching the Web
leuprolide depot 3.75mg IM vs subcutaneous difference formulation
Reading File
Reading File
Here is a clear breakdown of Leuprolide Depot 3.75 mg: IM vs. Subcutaneous:
Key Point: They Are Two Distinct Formulations, Not Just Different Routes
The IM and SC depot formulations of leuprolide acetate use different drug delivery technologies and are not interchangeable, even though the active ingredient is the same.
Intramuscular (IM) Depot - Lupron Depot®
| Feature | Detail |
|---|---|
| Brand | Lupron Depot® |
| Route | Intramuscular |
| Doses available | 3.75 mg/month; 11.25 mg/3 months |
| Technology | Microsphere (PLGA polymer microspheres) |
| Reconstitution | Powder + diluent, mixed before injection |
| Injection site | Gluteal muscle or deltoid |
3.75 mg IM dose indications:
- Endometriosis (monthly, up to 6 months; often co-packaged with norethindrone 5 mg/day)
- Uterine fibroids (with iron therapy prior to surgery)
- Prevention/management of menstrual bleeding associated with HCT
- Advanced prostate cancer (though higher doses are more common for this)
Subcutaneous (SC) Depot - Eligard®
| Feature | Detail |
|---|---|
| Brand | Eligard® |
| Route | Subcutaneous |
| Doses available | 7.5 mg/month; 22.5 mg/3 months; 30 mg/4 months; 45 mg/6 months |
| Technology | Atrigel® (liquid polymer that solidifies at injection site) |
| Reconstitution | Two-syringe mixing system |
| Injection site | Abdomen, upper arm, or thigh |
Critical note: The 3.75 mg dose is only available as an IM formulation (Lupron Depot). Eligard (the SC product) does not come in a 3.75 mg dose - its lowest dose is 7.5 mg/month.
Pharmacokinetic Differences
Although both formulations achieve castrate testosterone levels within ~4 weeks, their PK profiles differ due to the different delivery technologies:
- Lupron Depot (IM): Microsphere technology releases drug in a pulsatile-like manner
- Eligard (SC): Atrigel technology provides more continuous drug release, potentially with more sustained quantifiable leuprolide levels throughout the dosing interval
A head-to-head PK/PD comparison study found that while both achieve castration, the SC (Eligard) formulation produced more continuous circulating leuprolide levels, which may reduce the risk of testosterone "escapes" near the end of the dosing period.
Summary Table
| Lupron Depot (IM) | Eligard (SC) | |
|---|---|---|
| 3.75 mg available? | YES | NO |
| Technology | PLGA microspheres | Atrigel liquid polymer |
| Injection | Deep IM | SC |
| Interchangeable? | No - different PK profiles | No |
| Main indications | Endometriosis, fibroids, CPP, prostate Ca | Prostate Ca primarily |
Bottom line: If the prescriber specifies leuprolide depot 3.75 mg, this is Lupron Depot given IM - there is no SC equivalent at this dose. The SC formulations (Eligard) start at 7.5 mg and are primarily used for prostate cancer. The two product lines are not substitutable and clinicians/pharmacists should not switch between them without reassessment.
- Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 953
- Lippincott Illustrated Reviews Pharmacology, p. 1259
Luprodex 3.75 i. Vs sc
Searching the Web
Luprodex 3.75 mg leuprolide acetate IM vs subcutaneous route India
Luprodex 3.75 mg (Depot) - IM vs SC
Luprodex is the Bharat Serums & Vaccines (BSV) brand of leuprolide acetate 3.75 mg, widely used in India and other markets. Unlike Lupron Depot (IM only) or Eligard (SC only), Luprodex is specifically approved and labeled for BOTH intramuscular AND subcutaneous injection using the same vial.
What is Luprodex?
- Formulation: Sterile lyophilized powder (microspheres) containing leuprolide acetate 3.75 mg
- Technology: PLGA microspheres (same as Lupron Depot)
- Reconstitution: Powder vial + accompanying diluent → uniform suspension
- Pack contents: 1 vial microspheres + 1 ampoule diluent + 1 disposable syringe + 2 needles (one suitable for IM, one for SC) + 2 alcohol swabs
- Frequency: Once every month
The two needles in the pack are specifically provided to accommodate either IM or SC administration.
IM vs SC with Luprodex - Key Differences
| Feature | Intramuscular (IM) | Subcutaneous (SC) |
|---|---|---|
| Injection site | Gluteal muscle (or deltoid) | Abdomen, upper arm, thigh |
| Needle | Longer, wider gauge | Shorter, finer gauge |
| Pain/tolerability | More discomfort at site | Generally better tolerated |
| Absorption | Faster initial absorption, higher Cmax | Slower Cmax (~30% lower), but higher total AUC (~1.9x) |
| Drug release | Slightly more pulsatile | More sustained over the dosing interval |
| Patient preference | Typically needs HCP to administer | May be self-administered |
Pharmacokinetic Implications
Based on comparative PK/PD data (SC vs IM microsphere depot):
- SC route produces a lower peak (Cmax ~30% less) but higher overall exposure (AUC ~90% greater) due to more sustained release from the SC depot
- IM route gives a faster, higher initial peak but drug is cleared more quickly
- Both routes achieve castrate testosterone levels within 4 weeks and maintain suppression throughout the monthly dosing cycle
- The SC route's more continuous drug levels may theoretically reduce the risk of testosterone "escape" near the end of the dosing period
Clinical Indications (same for both routes)
- Endometriosis
- Uterine fibroids (as adjunct to iron therapy pre-surgery)
- Advanced prostate cancer
- Central precocious puberty (CPP) - dose is weight-based:
| Child's weight | Dose | Injections |
|---|---|---|
| ≤25 kg | 7.5 mg (2 vials) | 1 site |
| >25-37.5 kg | 11.25 mg (3 vials) | 2 sites |
| >37.5 kg | 15 mg (4 vials) | 2 sites |
Bottom Line
Luprodex 3.75 mg is approved for both IM and SC use from the same vial - this is a key difference from the Western market where IM (Lupron Depot) and SC (Eligard) are entirely separate products with different technologies. Both routes with Luprodex use the same microsphere formulation and achieve equivalent clinical suppression, with SC offering slightly more sustained drug exposure and potentially better patient comfort and the possibility of self-administration.
Why it is given in ivf before embryo transfer
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
I have enough from the textbook and my own knowledge to give a thorough answer. Here is the full explanation:
Why Leuprolide (Luprodex) is Given in IVF Before Embryo Transfer
There are two distinct contexts in IVF where leuprolide is used, each with a different rationale:
Context 1: During Ovarian Stimulation (Fresh IVF Cycle - Long Protocol)
The Problem it Solves: Premature LH Surge
When ovaries are stimulated with gonadotropins (FSH/hMG) to produce multiple follicles, the rising estrogen from multiple growing follicles can trigger a premature LH surge from the pituitary. This causes:
- Premature ovulation before egg retrieval
- Cycle cancellation
- Poor egg quality
How Leuprolide Prevents This ("Long Protocol / Long Down-Regulation Protocol")
| Phase | What Happens |
|---|---|
| Day 21 of previous cycle | Leuprolide started (1 mg/day SC) |
| First 1-3 days (Flare effect) | Initial burst of FSH & LH (agonist action) |
| After ~7-14 days | Pituitary GnRH receptors become desensitized and downregulated |
| Result | Pituitary is "switched off" - FSH and LH fall to baseline |
| Then | Gonadotropins (FSH injections) are added to stimulate follicles in a controlled, exogenous manner |
| Leuprolide continued at 0.5 mg | Prevents any spontaneous LH surge throughout stimulation |
| Until hCG trigger | Leuprolide stopped when oocyte maturation is triggered |
This gives the IVF team complete control over follicle development - no premature ovulation, predictable egg retrieval timing.
Context 2: Before Frozen Embryo Transfer (FET) - Endometrial Preparation
Why Leuprolide Depot 3.75 mg is Used Specifically Here
In a programmed/artificial FET cycle, the goal is to create a perfectly timed, receptive endometrium for the embryo. Leuprolide depot is given for:
1. Pituitary Suppression
- Suppresses endogenous FSH and LH completely
- Prevents the patient's own follicles from growing and producing estrogen unpredictably
- Stops spontaneous ovulation, which would disrupt the carefully timed endometrial preparation window
2. Endometrial "Quiet" State
- With the ovaries suppressed, the uterine lining is thin and quiescent
- Exogenous estradiol (tablets/patches/gel) is then given in controlled, escalating doses to build up the endometrium precisely
- Followed by progesterone to simulate the luteal phase
3. Synchronization
- The embryologist knows exactly when the endometrium is ready (progesterone is started on a set day)
- Embryo transfer is scheduled precisely at the window of implantation
FET Timeline with Leuprolide Depot
Day 1-2 of cycle → Leuprolide depot 3.75 mg (IM or SC)
↓ (~2-3 weeks suppression)
Confirm suppression (E2 < 50 pg/mL, thin endometrium on scan)
↓
Start estradiol (oral/transdermal) - builds endometrium
↓ (10-14 days, endometrium reaches 8mm+ trilaminar)
Start progesterone (vaginal/IM)
↓ (5 days for blastocyst / 3 days for Day 3 embryo)
Embryo Transfer ← window of implantation
Context 3: Leuprolide as the "Trigger" Itself
In high-risk patients (high AMH, PCOS, many follicles) at risk of ovarian hyperstimulation syndrome (OHSS), leuprolide 0.2-1 mg SC can be used as the oocyte maturation trigger instead of hCG. The flare effect causes a natural LH surge that triggers final egg maturation, but it is shorter-lived than hCG, greatly reducing OHSS risk.
Summary
| Use in IVF | Dose | Purpose |
|---|---|---|
| Long protocol (fresh cycle) | 1 mg/day SC → reduce to 0.5 mg | Prevent premature LH surge during stimulation |
| FET endometrial prep | 3.75 mg depot IM/SC | Suppress ovaries, allow controlled estrogen priming |
| OHSS prevention trigger | 0.2-1 mg SC single dose | Trigger oocyte maturation without hCG |
The depot 3.75 mg form is most commonly used for FET endometrial preparation because one injection provides a full month of pituitary suppression, making it practical and ensuring compliance without daily injections.
- Katzung's Basic & Clinical Pharmacology, 16th Ed. - Controlled Ovarian Stimulation section
- Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 953
This is a shared conversation. Sign in to Orris to start your own chat.